Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2025-05-25 Regulatory Filings
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial 2 pages 215.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Immutep's Phase II clinical trial for a cancer treatment has met its primary endpoint. It provides detailed information about the trial results, the drug, and the company, but it does not contain financial data, regulatory filings, or corporate governance information. It is not an earnings release, annual report, or any form of financial or regulatory filing. The content is focused on clinical trial results and scientific/medical information, which does not fit into any of the specific financial or corporate filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2025-05-25 English
High Response Rates achieved in Lung Cancer in INSIGHT-003 3 pages 281.8KB
Capital/Financing Update Classification · 70% confidence The document is a detailed announcement of clinical trial results for Immutep's drug combination in non-small cell lung cancer. It includes specific data on response rates, patient populations, safety, and next steps for the trial. The content is focused on clinical trial efficacy and safety data rather than financial results or regulatory filings. It is not an earnings release, annual report, or any financial report. It is also not a regulatory filing, board change, or voting result announcement. The document is a press release or investor update on clinical trial progress and results, which fits best under the category of Capital/Financing Update (CAP) as it relates to company progress and potential value drivers for investors, although it is not a direct financing announcement, it is the closest relevant category given the options. Confidence is moderate because the document is primarily clinical trial data but is presented as a company announcement relevant to investors.
2025-05-14 English
Excellent Overall Survival in Head & Neck Cancer Patients 2 pages 287.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical trial results for Immutep's drug combination in cancer treatment, including survival data and plans to meet with the FDA for regulatory discussions. It contains no financial statements, no detailed financial analysis, no regulatory certifications, or voting results. It is not a full annual or interim report, nor an earnings release. It is an update on clinical trial outcomes and regulatory engagement, typical of a Capital/Financing Update or Regulatory Filing. However, since it focuses on clinical trial results and regulatory next steps rather than fundraising or capital structure changes, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical progress and regulatory plans.
2025-05-04 English
Change in substantial holding 7 pages 104.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' under the Corporations Act 2001, Section 671B, which is a 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder, including specific share counts and percentages. This type of filing is a notification of changes in significant share ownership levels, typically required by regulatory authorities to disclose when a shareholder crosses certain ownership thresholds. The content is focused on shareholding changes and substantial holder disclosures, not on financial results, management changes, or other report types. Therefore, the appropriate classification is 'Major Shareholding Notification' (MRQ). The document length and detail support a confident classification.
2025-04-30 English
Immutep Quarterly Activities Report and Appendix 4C 9 pages 517.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Immutep Quarterly Activities Report & Appendix 4C Q3 FY25' and provides detailed updates on clinical trial progress, patient enrollment, intellectual property, and a comprehensive cash flow summary for the quarter ended 31 March 2025. It includes actual financial data such as cash flows from operating, investing, and financing activities, with specific figures and analysis. The presence of the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly financial report. The document is about a period shorter than a full fiscal year and contains substantive financial data and analysis, fitting the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a full quarterly report with financial statements and operational updates.
2025-04-28 English
Immutep Investor Update 6 pages 636.7KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Update' and dated April 2025. It contains detailed information about a Phase III clinical trial (TACTI-004) for a cancer drug, including trial design, regulatory progress, market overview, and company strategy. The content is focused on providing investors with updates on clinical progress, market conditions, and company outlook rather than presenting formal financial statements or regulatory filings. There is no indication of full financial performance data, audit information, or official regulatory filings. The document is a detailed presentation aimed at investors to inform them about the company's clinical and market progress, which fits the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or a formal report like an Annual Report or Earnings Release.
2025-04-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.